WO2010084998A1 - Procédé de prédiction de l'efficacité d'un médicament - Google Patents

Procédé de prédiction de l'efficacité d'un médicament Download PDF

Info

Publication number
WO2010084998A1
WO2010084998A1 PCT/JP2010/051304 JP2010051304W WO2010084998A1 WO 2010084998 A1 WO2010084998 A1 WO 2010084998A1 JP 2010051304 W JP2010051304 W JP 2010051304W WO 2010084998 A1 WO2010084998 A1 WO 2010084998A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
egfr
expression
drug
patients
Prior art date
Application number
PCT/JP2010/051304
Other languages
English (en)
Inventor
Michihiko Kuwano
Original Assignee
Kyushu University, National University Corporation
Kurume University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University, National University Corporation, Kurume University filed Critical Kyushu University, National University Corporation
Publication of WO2010084998A1 publication Critical patent/WO2010084998A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de prédiction de l'efficacité d'un médicament anticancéreux par détection de l'expression de YB-1 ou de la présence de 8-OHdG dans le noyau d'une cellule provenant d'un sujet, et prédiction de l'efficacité d'une thérapie pour traiter le cancer du sujet en fonction du résultat de l'étape de détection.
PCT/JP2010/051304 2009-01-26 2010-01-26 Procédé de prédiction de l'efficacité d'un médicament WO2010084998A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20597109P 2009-01-26 2009-01-26
US61/205,971 2009-01-26

Publications (1)

Publication Number Publication Date
WO2010084998A1 true WO2010084998A1 (fr) 2010-07-29

Family

ID=42356043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/051304 WO2010084998A1 (fr) 2009-01-26 2010-01-26 Procédé de prédiction de l'efficacité d'un médicament

Country Status (1)

Country Link
WO (1) WO2010084998A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0995499A (ja) * 1995-09-29 1997-04-08 Snow Brand Milk Prod Co Ltd 抗体及びそれを有効成分とする癌診断剤
WO2005073373A1 (fr) * 2004-01-29 2005-08-11 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Procédé de recueil d'un fragment endommagé d'adn
JP2005315763A (ja) * 2004-04-30 2005-11-10 Kyurin:Kk 胚細胞腫瘍の検出方法
JP2006521793A (ja) * 2003-02-06 2006-09-28 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー
JP2007121271A (ja) * 2005-09-30 2007-05-17 National Institute Of Advanced Industrial & Technology ８−ヒドロキシ−２’−デオキシグアノシンの測定方法及び測定のための装置
JP2008523114A (ja) * 2004-12-14 2008-07-03 メルテンス，ペーター・ルネ 炎症過程を決定するための方法およびこの治療のための医薬組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0995499A (ja) * 1995-09-29 1997-04-08 Snow Brand Milk Prod Co Ltd 抗体及びそれを有効成分とする癌診断剤
JP2006521793A (ja) * 2003-02-06 2006-09-28 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー
WO2005073373A1 (fr) * 2004-01-29 2005-08-11 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Procédé de recueil d'un fragment endommagé d'adn
JP2005315763A (ja) * 2004-04-30 2005-11-10 Kyurin:Kk 胚細胞腫瘍の検出方法
JP2008523114A (ja) * 2004-12-14 2008-07-03 メルテンス，ペーター・ルネ 炎症過程を決定するための方法およびこの治療のための医薬組成物
JP2007121271A (ja) * 2005-09-30 2007-05-17 National Institute Of Advanced Industrial & Technology ８−ヒドロキシ−２’−デオキシグアノシンの測定方法及び測定のための装置

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Annual Meeting of the Japanese Cancer Association, 2008.09.30", vol. 67TH, 30 September 2008, article KASHIHARA MASAKI ET AL.: "Nuclear YB-1 localization is closely correlated with poor prognosis involving EGFR family expression in lung cancer, Proceedings.", pages: 99 *
YASUSHI YATABE ET AL.: "EGFR Mutation in Lung Cancers", BIOTHERAPY, vol. 20, no. 2, 30 March 2006 (2006-03-30), pages 223 - 230 *
YOSHINORI SAKATA ET AL.: "The detection of EGFR mutation (L858R) by immunohistochemistry", JOURNAL OF TOKYO MEDICAL UNIVERSITY, vol. 66, no. 3, 25 July 2008 (2008-07-25), pages 360 - 367 *

Similar Documents

Publication Publication Date Title
Lee et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
Pailler et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non–small-cell lung cancer
Ha et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas
Park et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
Soria et al. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects
Zhou et al. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages
Lee et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
Qin et al. Hypoxia-driven mechanism of vemurafenib resistance in melanoma
US20130230511A1 (en) Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
EP2681330B1 (fr) Utilisation de la protéine olfactomédine-4 (olfm4) dans le diagnostic du cancer colorectal
Read et al. The proto‐oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer
JP2021503308A (ja) 診断方法
KR20160086326A (ko) 핵산 바이오마커 및 이의 용도
Xie et al. Ski regulates Smads and TAZ signaling to suppress lung cancer progression
Tantraworasin et al. Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non-small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies
Schirripa et al. Biomarker-driven and molecular targeted therapies for colorectal cancers
Kalamanathan et al. The mutational profile of sporadic epithelial ovarian carcinoma
Guo et al. Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer
Abou-Bakr et al. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma
Prudkin et al. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications
Kawahara et al. The close correlation between 8-hydroxy-2′-deoxyguanosine and epidermal growth factor receptor activating mutation in non–small cell lung cancer
Guo et al. Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections
Guillaudeau et al. Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization
WO2016161153A2 (fr) Procédés de diagnostic et de pronostic du cancer colorectal
Łaczmańska et al. Personalised medicine in lung cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733599

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10733599

Country of ref document: EP

Kind code of ref document: A1